Revisiting the copd mega-trials in the new decade: The end of the road or just a new beginning?
More details
Hide details
Editorial Board Pneumon
Corresponding author
Stelios Loukides   

Smolika 2 16673 Athens
Pneumon 2011;24(1):27-29
Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. Α 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8.
Troosters T, Celli B, Lystig T, et al. Uplift Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65-73.
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
enkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir Res 2009;10:59.
Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: a pre-specified analysis of the fouryear trial of tiotropium (UPLIFT). Respir Med 2010;104:1659-67.
Welte T, Miravitlles M, Hernandez P, et al. Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2009;180:741-50.
Aaron SD, Vandemheen KL, Fergusson D, et al; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55.
Dahl R, Chung KF, Buhl R, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473-9.
Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.
Rabe KF. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med 2010;4:543-55.
Kostikas K, Bakakos P, Loukides S. Phosphodiesterase 4 inhibitors: A new treatment option for copd. Are we there yet? Pneumon 2009;4:290-5.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: http://www.goldcopd.com.
Kostikas K, Bouros D. ”Show me the money”: a fair criticism of economic studies on inhaled bronchodilators in COPD. BMC Pulm Med 2010;10:48.
Decramer M, Cooper CB. Treatment of COPD: the sooner the better? Thorax 2010;65:837-41.
Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64:939-43.
Bakakos P, Kostikas K, Loukides S. COPD and co-morbidities. Pneumon 2010;1:21-7.
Journals System - logo
Scroll to top